Abstract: The present invention relates to a method for reducing the competitive fitness of an organism hemizygous for a transgenic locus compared to the organism homozygous for the transgenic locus comprising the steps of: (a) reducing the expression of a haploinsufficient gene in the organism, wherein said reduction is conveyed by a transgenic locus in the organism; and (b) rescuing the reduced expression in the organism, wherein said rescue is conveyed by the same transgenic locus in the organism, yielding an organism which is less competitively fit if hemizygous for the transgenic locus than if homozygous for the transgenic locus.

Abstract: The present invention relates to well-defined synthetic saccharides of general formula (I) that are related to the repeating unit of Streptococcus pneumoniae serotype 5 capsular polysaccharide and conjugates thereof. The conjugates and pharmaceutical compositions containing said conjugates are useful for prevention and/or treatment of diseases associated with Streptococcus pneumoniae, and more specifically against diseases associated with Streptococcus pneumoniae serotype 5. Furthermore, the synthetic saccharides of general formula (I) are useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae bacteria.

Abstract: The present invention relates to the field of synthesizing and biologically evaluating of a novel class of carbohydrate-based vaccines. The new vaccines consist of a multi-modular structure which allows applying the vaccine to a whole variety of pathogenes. This method allows preparing vaccines against all pathogens expressing immunogenic carbohydrate antigens. As conjugation of antigenic carbohydrates to proteins is not required the conjugate vaccine is particularly heat stable. No refrigeration is required, a major drawback of protein-based vaccines.

Abstract: A magnetic closure device has two complementary magnetic closure elements. Each of the two complementary magnetic closure elements includes an elongated magnet carrier having a single direction of main extension, and a plurality of permanent magnets supported by the magnet carrier in defined positions along the direction of main extension. Each of the permanent magnets is permanently magnetized either longitudinally or diametrically with regard to the direction of main extension. The permanent magnets following to each other in the direction of main extension are arranged in a closure alignment pattern having a magnetic non-repetition length extending over three or more of the permanent magnets. The magnet carrier is bendable in at least one direction orthogonal to the direction of main extension.

Abstract: A computer-implemented method for determining a relevance of a node in a network. A digital representation of a local neighborhood structure of the node in the network is obtained in a computer-readable non-volatile memory. A numerical value characteristic of the node's relevance is determined, and output to a user. The numerical value is determined based on the neighborhood structure of the node.

Abstract: The present invention relates to a method of producing a phantom resembling a human or animal organ or tissue, the phantom comprising at least one first region having at least one tissue like property and at least one cavity having a plurality of hollow branches connected thereto, with at least some of the plurality of hollow branches being formed such that they project into the first region having tissue like properties. The invention further relates to a method of making the first structure and to a corresponding phantom.

Abstract: This invention relates to extracellular protein-protein interactions and their possible therapeutic uses. More particularly, this invention describes the interaction between Draxin, particularly fragments binding to ?-Netrins comprising SEQ ID NO.:1, 2 or 3, and variants thereof, with ?-Netrins, and the use of this interaction to disrupt ?-Netrin/Netrin receptor interactions. The invention also relates to diagnostic and/or therapeutic uses of Draxin or fragments or variants thereof, as well as to an antibody against Draxin inhibiting binding of Draxin to ?-Netrins. Further, the invention relates to fragments of ?-Netrins, in particular Draxin-binding Netrin1-fragments comprising SEQ ID NO.: 51 and variants thereof, as well as to an antibody against ?-Netrins inhibiting binding of ?-Netrins to Netrin receptors.

Abstract: The present invention refers to a method for binding a polycarboxylic acid to a solid phase. Further, the invention refers to a solid phase having a polycarboxylic acid immobilized thereto and methods of using the solid phase, e.g. for purifying His-tagged recombinant polypeptides.

Abstract: The present invention relates to a nucleic acid molecule encoding a fusion protein, wherein the nucleic acid molecule comprises: (a) a first nucleic acid sequence encoding a first biosensor, wherein said first biosensor is a first molecule capable of interacting with a second molecule; (b) a second nucleic acid sequence encoding an effector-activating module, wherein the effector-activating module comprises a nucleic acid sequence encoding a first part of a protease, wherein said first part of the protease is capable of interacting with a second part of said protease to form an active form of said protease; (c) a third nucleic acid sequence encoding a third biosensor comprising a protease cleavage site, wherein the protease cleavage site is sterically occluded in the absence of a stimulus for said third biosensor and wherein the protease cleavage site becomes accessible in the presence of said stimulus.

Abstract: Disclosed is a method including receiving visual input comprising a human within a scene, detecting a pose associated with the human using a trained machine learning model that detects human poses to yield a first output, estimating a shape (and optionally a motion) associated with the human using a trained machine learning model associated that detects shape (and optionally motion) to yield a second output, recognizing the scene associated with the visual input using a trained convolutional neural network which determines information about the human and other objects in the scene to yield a third output, and augmenting reality within the scene by leveraging one or more of the first output, the second output, and the third output to place 2D and/or 3D graphics in the scene.

Abstract: A pulse light source device (100) for creating fs output laser pulses (1, 1.1, 1.2, 1.3) having CEP stability comprises a pulse source device (10) creating primary ps laser pulses, a first beam splitting device (13) splitting the primary ps laser pulses to first ps laser pulses (2.1) and second ps laser pulses (2.2), a pulse shortening device (20) creating sub-ps laser pulses (3) by shortening and spectrally broadening the first ps laser pulses (2.1), a primary supercontinuum generation device (30) creating primary fs laser pulses (4), a pulse stretcher device (40) creating stretched ps laser pulses (5, 5.1) by stretching the primary fs laser pulses (4), a optical parametric chirped-pulse amplification device (51) creating amplified ps laser pulses (6, 6.1) on the basis of the stretched ps laser pulses (5, 5.1) and the second ps laser pulses (2.2); a phase stabilization device (61) creating CEP stable ps laser pulses (7, 7.1) by difference frequency generation of the amplified ps laser pulses (6, 6.

Abstract: Provided is a 4-oxoquinoline compounds of the formula (I) (I) wherein A is selected from diradicals of the formulae (A.1), (A.2), (A.3), (A.4), (A.5) and (A.6), (A.1) (A.2) (A.3) (A.4) (A.5) (A.6) wherein R1, R2a, R2b, R3, R3a, if present R4a, R4b, R 5a, R5b, R6a, R6b, R6c, R6d, Rn1, Rn2, Rn3, Rn4, Rm5, Rm6, Rm7, Rm8, R7, R8a, R9 and R9a are as defined in the claims and in the description. Also provided is a method for their preparation and their use.

Abstract: The invention relates to a light microscope for examining microscopic objects with high throughput. The microscope comprises a light source for illuminating a measuring zone, a sample vessel, in which the microscopic objects can be successively moved into the measuring zone, and a detection device for measuring detection light, which originates from a microscopic object located in the measuring zone. According to the invention, the microscope is characterized in that the imaging means comprise a detection lens having a stationary front optics and movable focusing optics, wherein the focusing optics is arranged behind the front optics and in front of an intermediate image plane, and can be adjusted for the height adjustment of a detection plane. The invention further relates to a corresponding microscopy method.

Abstract: A hollow-core anti-resonant-reflecting fibre (HC-AF) includes a hollow-core region, an inner cladding region, and an outer cladding region. The hollow-core region axially extends along the HC-AF. The inner cladding region includes a plurality of anti-resonant elements (AREs) and surrounds the hollow-core region. The outer cladding region surrounds the inner cladding region. The hollow-core region and the plurality of AREs are configured to provide phase matching of higher order hollow-core modes and ARE modes in a broadband wavelength range.

Abstract: The present invention relates to a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer, comprising the measurement of the amounts of specific isoforms of GATA6 and/or NKX2-1 in a sample of said subject. Furthermore, the present invention relates to a composition for use in medicine comprising (an) inhibitor(s) of specific isoforms of GATA6 and/or NKX2-1. Additionally, the present invention relates to a kit for use in a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer.

Abstract: Spherical microcapsules including light reflecting solid integral particles reflecting incoming light in a defined direction for determining the position and orientation of the microcapsule are produced by preparing a first liquid phase containing a first polymerization partner; preparing a second liquid phase containing a second polymerization partner, the first liquid phase not being soluble in the second liquid phase, and the second polymerization partner being configured to polymerize with the first polymerization partner under polymerization conditions; dispersing the solid particles in the first liquid phase; forming droplets of the first liquid phase including at least one solid particle; and immersing the droplets in the second liquid phase under the polymerization conditions.

Abstract: The present invention relates to a vasopressin receptor 1B (V1B) antagonist for use in the treatment of depressive symptoms and/or anxiety symptoms in patients showing an elevated arginine vasopressin (AVP) level and/or an elevated copeptin level. The present invention further relates to a method for predicting the treatment response to a V1B antagonist in patients with depressive symptoms and/or anxiety symptoms.

Abstract: A training apparatus includes an elastic band; a device for continuously determining an actual configuration of the training apparatus during exercise, e.g. a stretch of the elastic band or a 2D or 3D position of said device; and for generating a control signal for an audio device, the control signal being at least partially based on the actual configuration of the training apparatus; and for outputting the control signal.

Abstract: The present invention relates to a device, comprising at least one layer of an active material having a first optical thickness, the active material being selected so as to experience a change (i) of at least one size dimension, (ii) of the resistance, (iii) of the refractive index or (iv) combinations of two or more of the foregoing, when the active material is subjected to a change in environment, wherein at least one and preferably all of the layers of the at least one layer of the active material is composed of at least two nanosheets of the active material, with the at least two nanosheets randomly overlapping one another. The invention further relates to a nanosheet of active material and to a use of the nanosheet of the material.

Abstract: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response.